TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

STOCK ALERT: MoonLake Immunotherapeutics (MLTX) Investors may be Eligible for Compensation in Securities Class Action – Contact BFA Law by December 15 Deadline

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Bleichmar Fonti & Auld Llp
STOCK ALERT: MoonLake Immunotherapeutics (MLTX) Investors may be Eligible for Compensation in Securities Class Action – Contact BFA Law by December 15 Deadline

MoonLake Immunotherapeutics faces a securities class action lawsuit after reporting disappointing Phase 3 VELA trial results for its investigational drug sonelokimab, causing its stock price to drop nearly 90%.

Insights
MLTX   negative

Stock price dropped 90% after failed clinical trials, potential regulatory approval challenges, and allegations of misleading investors about drug's clinical benefits